Cancer-associated fibroblasts induce antigen-specific deletion of CD8 <sup>+</sup> T Cells to protect tumour cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29507342.
- Also identified by DOI 10.1038/s41467-018-03347-0 and PMC identifier 5838096.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Tumours have developed strategies to interfere with most steps required for anti-tumour immune responses. Although many populations contribute to anti-tumour responses, tumour-infiltrating cytotoxic T cells dominate, hence, many suppressive strategies act to inhibit these. Tumour-associated T cells are frequently restricted to stromal zones rather than tumour islands, raising the possibility that the tumour microenvironment, where crosstalk between malignant and "normal" stromal cells exists, may be critical for T cell suppression. We provide evidence of direct interactions between stroma and T cells driving suppression, showing that cancer-associated fibroblasts (CAFs) sample, process and cross-present antigen, killing CD8<sup>+</sup> T cells in an antigen-specific, antigen-dependent manner via PD-L2 and FASL. Inhibitory ligand expression is observed in CAFs from human tumours, and neutralisation of PD-L2 or FASL reactivates T cell cytotoxic capacity in vitro and in vivo. Thus, CAFs support T cell suppression within the tumour microenvironment by a mechanism dependent on immune checkpoint activation.
Medical subject headings
- Antigens, Neoplasm
- CD8-Positive T-Lymphocytes
- Cancer-Associated Fibroblasts
- Cytoprotection